Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 2992-3000

  Hirai, Hiroshi ^a   Iwasawa, Yoshikazu ^a   Okada, Megumu ^a   Arai, Tsuyoshi ^a   Nishibata, Toshihide ^a   Kobayashi, Makiko ^a   Kimura, Toshifumi ^a   Kaneko, Naoki ^a   Ohtani, Junko ^a   Yamanaka, Kazunori ^a   Itadani, Hiraku ^a   Takahashi Suzuki, Ikuko ^a   Fukasawa, Kazuhiro ^a   Oki, Hiroko ^a   Nambu, Tadahiro ^a   Jiang, Jian ^a   Sakai, Takumi ^a   Arakawa, Hiroharu ^a   Sakamoto, Toshihiro ^a   Sagara, Takeshi ^a   Yoshizumi, Takashi ^a   Mizuarai, Shinji ^a   Kotani, Hidehito ^a   more..

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE 1; GEMCITABINE; GEMZER; MK 1775; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; TYROSINE; UNCLASSIFIED DRUG; WEE1 KINASE; WEE1 KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN B; DNA DAMAGE; DRUG SYNERGISM; FLOW CYTOMETRY; HELA CELLS; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RATS; RATS, INBRED F344; RATS, NUDE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70949083026     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0463     Document Type: Article

References (28)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320 (Pubitemid 41130944)
2. Zhou BBS, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004;4:1-10.
3. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
4. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000;33:261-274
5. 2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-519
6. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment ofca ncer. Br J Cancer 2008;98:523-528 (Pubitemid 351214533)
7. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-1960 (Pubitemid 46649860)
8. cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992;257:1955-1957.
9. Igarashi M, Nagata A, Jinno S, Suto K, Okayama H. Wee1+-like gene in human. Nature 1991;353:80-83
10. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1-Hu CDK tyrosine 15-kinase during the cell cycle. EBMO J 1995;14:1878-1891
11. cdc2 exclusively on Tyr15. EBMO J 1993;12:75-85.
12. 2 arrest in human cells. J Cell Biol 1996;134:963-970
13. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997;16:545-554 (Pubitemid 27067784)
14. 2 checkpoint and induces apoptosis. Cancer Biol Ther 2004;3:305-313
15. 2 checkpoint abrogator. Cancer Res 2001;61:8211-8217
16. Bartz SR, Zhang Z, Burchard J, et al. Small interfering RNA screen reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006;26:9377-9386
17. Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 1995;270:86-90.
18. Manegold C. Gemicitabine (Gemzar) in non-small cell ling cancer. Exp Rev Anticancer Ther 2004;4:345-360
19. Kose MF, Meydanli MM, Tulunay G. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. Exp Rev Anticancer Ther 2006;6:437-443
20. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 2004;4:53-81.
21. Hashimoto O, Shinkawa M, Torimura T, et al. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido[2,3-d]pyrimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006;6:292.
22. Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology 2001;108:829-830
23. Egawa S, Matsumoto K, Iwamura M, Uchida T, Kuwao S, Koshiba K. Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan. Jpn J Clin Oncol 1997;27:394-400. (Pubitemid 127519261)
24. Cdc2. Cancer 2003;98:1123-1130
25. Skaland I, Janssen EA, Gudlaugsson E, et al. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years ofage. Mod Pathol 2007;20:1307-1315 (Pubitemid 350126856)
26. T1799A(V600E) mutation in primary melanoma. J Invest Dermotol 2007;127:900-905
27. Li KKW, Ng IOL, Fan ST, Albrecht JH, Yamashita K, Poon RYC. Activation ofcyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma. Liver 2002;22:259-268 (Pubitemid 34846365)
28. Mizuarai S, Yamanaka K, Itadani H, et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 2009;8:34.